Santa Clara University, through its Department of Bioengineering and Healthcare Innovation and Design Program, is excited to host a San Francisco Bay Area NIIMBL eXperience program designed to inspire and support college students to explore careers in biotechnology and biopharmaceutical manufacturing. NIIMBL eXperience @SCU will leverage the unique and entrepreneurial culture of the biopharmaceutical industry cluster in the SF Bay Area to position the sector as a dynamic, innovative, and rewarding field of study and work.
The week-long program, designed to introduce students from underrepresented communities to career possibilities in the biopharmaceutical industry, will partner with local industry partners to deliver a holistic series of industry visits, technical sessions and panels, professional mentoring, and connections to internship pipelines. Participants will visit prototype manufacturing sites and hear from panels with insights into the compelling problems and transformative solutions of our time. They will also have access to exemplars, mentors, and professional development support to help accelerate their career paths.
NIIMBL eXperience @SCU
- When: Sunday, June 22, 2025 - Saturday, June 28, 2025
- Where: Program hosted on the SCU campus in the Silicon Valley, California with housing, meals, transportation to SCU, and to multiple off-campus experiences included.
- Who: Community college students and undergraduate first- and second-year students within STEM-based majors (e.g. engineering, chemistry, biology, public health, physics, etc).
- Deadline: Applications due by 5 PM Eastern Time on February 7, 2025
- Stipend: Accepted applicants will receive a $1000 stipend for this all-expenses paid program.
The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) aims to accelerate biopharmaceutical innovation, enable more efficient and rapid manufacturing capabilities, and train a world-leading biopharmaceutical manufacturing workforce.
This project was developed with an award from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) and financial assistance from the U.S. Department of Commerce, National Institute of Standards and Technology (70NANB21H086).